title: A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of a triple nucleoside reverse transcriptase inhibitor combination of zidovudine, lamivudine, and didanosine therapy.
  
  
  METHODS
  A randomized open-label trial.
  
  
  METHODS
  Antiretroviral-naive HIV-infected patients with CD4+ cell counts of 100 to 500 cells/microl.
  
  
  METHODS
  A total of 106 patients were randomly assigned to 300 mg of zidovudine (200 mg for body weight <60 kg) twice daily plus 150 mg of lamivudine twice daily plus 200 mg of didanosine (125 mg for body weight <60 kg) twice daily (n = 53) or to zidovudine plus lamivudine (n = 53) for 48 weeks.
  
  
  METHODS
  Degree and duration of reduction of HIV-1 RNA load and increase in CD4+ cell counts from baseline and development of drug-related toxicities.
  
  
  RESULTS
  At 48 weeks, triple drug therapy showed greater declines in plasma HIV-RNA levels from the beginning of treatment than double drug therapy (1.86 vs. 1.15 log10 copies/ml, respectively; p <.001). The proportions of patients with HIV-RNA <50 copies/ml in an intention-to-treat analysis were 54.7% (29 of 53 patients) and 11.3% (6 of 53 patients) in the triple and double drug therapy, respectively (p =.001). There was no significant difference in increase of CD4 count.
  
  
  CONCLUSIONS
  Triple drug therapy with zidovudine, lamivudine, and didanosine was significantly more effective in inducing sustained immunologic and virologic responses than the double combination of zidovudine and lamivudine.
authors.affiliation: The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Bangkok 10330, Thailand. chaiwat.u@chula.ac.th
authors.forename: C
authors.initials: C
authors.lastname: Ungsedhapand
authors.forename: E D
authors.initials: ED
authors.lastname: Kroon
authors.forename: S
authors.initials: S
authors.lastname: Suwanagool
authors.forename: K
authors.initials: K
authors.lastname: Ruxrungtham
authors.forename: N
authors.initials: N
authors.lastname: Yimsuan
authors.forename: A
authors.initials: A
authors.lastname: Sonjai
authors.forename: S
authors.initials: S
authors.lastname: Ubolyam
authors.forename: S
authors.initials: S
authors.lastname: Buranapraditkun
authors.forename: S
authors.initials: S
authors.lastname: Tiengrim
authors.forename: N
authors.initials: N
authors.lastname: Pakker
authors.forename: C
authors.initials: C
authors.lastname: Kunanusont
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: D A
authors.initials: DA
authors.lastname: Cooper
authors.forename: P
authors.initials: P
authors.lastname: Phanuphak
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013785:Thailand; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D016049:Didanosine